# Safety, Tolerability, PK, PD, Immunogenicity and Efficacy of TWP-102 in Patients With Advanced Malignancies.

> **NCT05024305** · PHASE1 · UNKNOWN · sponsor: **Shandong TheraWisdom Biopharma Co., Ltd.** · enrollment: 81 (estimated)

## Conditions studied

- Advanced Malignancies

## Interventions

- **DRUG:** TWP-102 injection

## Key facts

- **NCT ID:** NCT05024305
- **Lead sponsor:** Shandong TheraWisdom Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-08
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-06-30
- **Target enrollment:** 81 (ESTIMATED)
- **Last updated:** 2022-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05024305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05024305, "Safety, Tolerability, PK, PD, Immunogenicity and Efficacy of TWP-102 in Patients With Advanced Malignancies.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05024305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*